Hsbc Holdings PLC Grows Stock Holdings in Halozyme Therapeutics, Inc. $HALO

Hsbc Holdings PLC boosted its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 1,202.4% during the 4th quarter, Holdings Channel.com reports. The firm owned 82,323 shares of the biopharmaceutical company’s stock after purchasing an additional 76,002 shares during the quarter. Hsbc Holdings PLC’s holdings in Halozyme Therapeutics were worth $5,584,000 as of its most recent filing with the SEC.

A number of other institutional investors have also modified their holdings of the stock. Measured Wealth Private Client Group LLC raised its position in Halozyme Therapeutics by 51.5% during the fourth quarter. Measured Wealth Private Client Group LLC now owns 365 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 124 shares in the last quarter. Larson Financial Group LLC boosted its position in Halozyme Therapeutics by 3,118.2% in the 3rd quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 343 shares in the last quarter. Clearstead Advisors LLC grew its stake in shares of Halozyme Therapeutics by 107.7% during the 3rd quarter. Clearstead Advisors LLC now owns 511 shares of the biopharmaceutical company’s stock worth $37,000 after purchasing an additional 265 shares during the period. Harbour Investments Inc. increased its holdings in shares of Halozyme Therapeutics by 152.5% during the 4th quarter. Harbour Investments Inc. now owns 616 shares of the biopharmaceutical company’s stock valued at $41,000 after purchasing an additional 372 shares in the last quarter. Finally, Wexford Capital LP purchased a new position in shares of Halozyme Therapeutics during the 3rd quarter valued at approximately $70,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Up 3.2%

HALO stock opened at $74.96 on Friday. The company has a current ratio of 2.76, a quick ratio of 2.33 and a debt-to-equity ratio of 8.81. The firm has a 50-day moving average of $68.42 and a two-hundred day moving average of $68.86. Halozyme Therapeutics, Inc. has a 12 month low of $51.06 and a 12 month high of $82.22. The company has a market cap of $8.89 billion, a price-to-earnings ratio of 26.96, a PEG ratio of 0.31 and a beta of 0.88.

Halozyme Therapeutics (NASDAQ:HALO) last announced its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.06. Halozyme Therapeutics had a net margin of 23.13% and a return on equity of 187.91%. The firm had revenue of $376.71 million for the quarter, compared to analysts’ expectations of $358.60 million. During the same quarter in the previous year, the company posted $1.11 EPS. The company’s revenue was up 42.2% compared to the same quarter last year. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. As a group, analysts forecast that Halozyme Therapeutics, Inc. will post 7.54 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Halozyme Therapeutics news, Director Bernadette Connaughton sold 1,625 shares of the stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $66.21, for a total value of $107,591.25. Following the sale, the director owned 43,669 shares of the company’s stock, valued at $2,891,324.49. This trade represents a 3.59% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 10,000 shares of Halozyme Therapeutics stock in a transaction on Wednesday, June 3rd. The stock was sold at an average price of $69.07, for a total transaction of $690,700.00. Following the sale, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at approximately $53,030,564.60. This trade represents a 1.29% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 93,250 shares of company stock worth $6,299,746 over the last three months. Insiders own 2.50% of the company’s stock.

Analysts Set New Price Targets

HALO has been the subject of a number of analyst reports. Benchmark reiterated a “buy” rating on shares of Halozyme Therapeutics in a research report on Wednesday, June 3rd. Weiss Ratings upgraded Halozyme Therapeutics from a “hold (c)” rating to a “buy (b-)” rating in a research report on Tuesday, May 12th. HC Wainwright restated a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, June 16th. UBS Group reaffirmed a “buy” rating and issued a $90.00 price target on shares of Halozyme Therapeutics in a report on Wednesday, June 3rd. Finally, Morgan Stanley lowered their price target on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 12th. Eight analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $81.60.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.